PRME vs MRNA

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 03, 2026

PRME

59.2
AI Score
VS
PRME Wins

MRNA

51.3
AI Score

Investment Advisor Scores

PRME

59score
Recommendation
HOLD

MRNA

51score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric PRME MRNA Winner
Revenue 3.79M 534.00M MRNA
Net Income -155.06M -2.13B PRME
Net Margin -4087.1% -397.9% MRNA
Operating Income -159.74M -2.20B PRME
ROE -95.8% -31.4% MRNA
ROA -40.3% -19.4% MRNA
Total Assets 385.01M 10.96B MRNA
Cash 71.40M 1.72B MRNA
Current Ratio 6.61 2.29 PRME
Free Cash Flow -129.55M -1.25B PRME

Relative Price Performance (Last 90 Days)

PRME 1M: -27.4% · 3M: -17.6% MRNA 1M: -30.9% · 3M: +21.5%

Current Technical Phase

PRME

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 36

RSI (14): 36.5 · Price: $2.81

MRNA

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 41

RSI (14): 41.4 · Price: $55.14

Fundamentals Snapshot

Metric PRME MRNA
Market Cap
Forward P/E -3.3 -11.1
Trailing P/E
Revenue (TTM)
Revenue Growth -0.4% 0.0%
Gross Margin -37.2% -0.7%
Operating Margin -59.2% -5.6%
EPS -1.23 -7.98
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, PRME is currently the stronger investment candidate, winning 4 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.